Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

768P - Investigation of CD73 expression in response to immunotherapy in pan-cancer

Date

10 Sep 2022

Session

Poster session 14

Topics

Tumour Immunology;  Pathology/Molecular Biology;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Yonggang Wang

Citation

Annals of Oncology (2022) 33 (suppl_7): S331-S355. 10.1016/annonc/annonc1058

Authors

Y. Wang1, M. Liu2, X. Hu2

Author affiliations

  • 1 Hepatological Surgery Department, Hunan Provincial People's Hospital, 410000 - Changsha/CN
  • 2 Medical Department, 3D Medicines, Inc., 510000 - Shanghai/CN
More

Abstract 768P

Background

CD73, also known as NT5E, is a cell surface glycosylphosphatidlinositol-anchored glycoprotein, which can produce adenosine to inhibits anti-tumor immunity or immune evasion and leads to tumor growth and/or metastasis. Therefore, CD73 as a new immune checkpoint has attracted wide attention. However, there was few clinical study has explored the correlation between the expression of CD73 and the efficacy of PD-1 /L1 inhibitors.

Methods

The data of 4751 patients with solid tumor from TCGA were used to analyze the correlation between NT5E and prognosis, and RNA-sequencing expression (level 3) profiles and corresponding clinical information for pan-cancer were downloaded from the TCGA dataset for Spearman correlation analysis of MSI/TMB/CD276 and NT5E gene expression. Immune score evaluation was conducted via immunedeconv R package. An independent cohort (the Hwang study cohort) with NT5E data from 20 patients with NSCLC, was used to analyze the prognostic effect of NT5E on PD-1 /L1 inhibitors.

Results

In TCGA cohort, higher CD73/NT5E expression was associated with worse prognosis in 9 types of solid tumors, including HNSC, UVM, TGCT, STAD, LUAD, LUSC, PAAD, and MESO, most independent of TMB/MSI status. Interestingly, it`s a positive correlation between PD-L1 and NT5E expression in tumors (R=0.23, P<0.001), but a negative correlation in normal tissues (R=-0.19, P<0.001). However, the immune status of LUAD found that the TMB (P<0.001), MSI (P<0.001), and PD-L1 (P<0.001) in the high-expression NT5E group was significantly higher than low-expression group. Moreover, the expression of NT5E was significantly associated with high infiltration of B cells (P<0.001), but with low infiltration of M2 macrophages (P<0.01)and myeloid dendritic cells (P<0.001). In Hwang study cohort, high CD73 expression had significantly better PFS (P=0.005; HR = 0.3; 95% CI, 0.11–0.84) after PD-1/L1 inhibitors in NSCLC patients.

Conclusions

Our results highlight the significance of CD73 as a potential target for cancer immunotherapy and as a promising biomarker for predicting ICI response in several tumors such as LUAD for its expression levels seem to be correlated with the status of immunotherapy-associated signatures.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.